Regen BioPharma Inc (RGBP)

[trucker20]

REGEN one of key Players Operating in Global Market for Acquired Aplastic Anemia

The global aplastic anemia treatment market is highly concentrated due to the presence of key players. A large number of manufacturers hold a major share in their respective region. Major companies in the market are engaged in developing new products and obtaining approvals. For instance, in November 2018, Novartis AG received the approval from the Food and Drug Administration for Promacta as the first line treatment for aplastic anemia. In September 2016, Regen BioPharma Inc. submitted an additional data application for orphan drug, HemaXellerate. In September 2015, Novartis AG received an approval from the European Commission for Revolade for the treatment of aplastic anemia in adult patients.